Compare Eli Lilly And Co (LLY) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Tilray Brands Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Eli Lilly And Co is far larger — about 1960.3× Tilray Brands Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Tilray Brands Inc for 31 Days on average.
| LLY | TLRY | |
|---|---|---|
Market Cap | $1.04T | $530.54M |
Volume | 3,064,878 | 9,099,075 |
Sector | Health | Health |
52-Week High | $1.28K | $21.00 |
52-Week Low | $799.57 | $3.57 |
Typical Hold Time | 93 Days | 31 Days |
Enterprise Value | $1.09T | $684.46M |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Tilray Brands (TLRY) trades at $3.59, down 3.36% on the day and near 52-week lows, with bearish technical indicators dominating. The company reported $821 million in revenue for 2025 but posted a massive $2.19 billion net loss due to impairment charges. Recent earnings have consistently missed expectations, though analyst consensus remains cautiously optimistic with a $65.01 price target. The stock faces significant headwinds from ongoing profitability challenges and cannabis industry volatility.
TLRY presents a high-risk opportunity with potential upside if management can achieve profitability and capitalize on cannabis reform catalysts. However, persistent losses, negative cash flow, and competitive pressures create substantial downside risk. Investors should weigh the speculative nature against potential regulatory catalysts in the coming months.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
